Which has better valuation & earnings, HQY or DXCM?

DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HealthEquity $1.31B 6.71 $215.20M $2.67 39.48 DexCom $4.66B 7.47 $836.30M $2.53 36.50

Is HQY or DXCM more profitable?

DexCom has a net margin of 20.12% compared to HealthEquity's net margin of 17.25%. DexCom's return on equity of 35.94% beat HealthEquity's return on equity. Company Net Margins Return on Equity Return on Assets HealthEquity 17.25% 14.75% 9.22% DexCom 20.12% 35.94% 14.75%

Does the media prefer HQY or DXCM?

In the previous week, DexCom had 10 more articles in the media than HealthEquity. MarketBeat recorded 23 mentions for DexCom and 13 mentions for HealthEquity. DexCom's average media sentiment score of 1.65 beat HealthEquity's score of 1.40 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthEquity 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 22 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, PODD or DXCM?

DexCom has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 3.79 $247.10M $5.35 27.69 DexCom $4.66B 7.47 $836.30M $2.53 36.50

Is PODD or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Insulet's net margin of 12.29%. DexCom's return on equity of 35.94% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 12.29% 29.29% 13.31% DexCom 20.12% 35.94% 14.75%

Does the media favor PODD or DXCM?

In the previous week, Insulet had 16 more articles in the media than DexCom. MarketBeat recorded 39 mentions for Insulet and 23 mentions for DexCom. DexCom's average media sentiment score of 1.65 beat Insulet's score of 0.42 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 11 Very Positive mention(s) 1 Positive mention(s) 27 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DexCom 22 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings and valuation, ABT or DXCM?

Abbott Laboratories has higher revenue and earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abbott Laboratories $44.33B 4.55 $6.52B $3.09 37.74 DexCom $4.66B 7.47 $836.30M $2.53 36.50

Does the media favor ABT or DXCM?

In the previous week, Abbott Laboratories had 43 more articles in the media than DexCom. MarketBeat recorded 66 mentions for Abbott Laboratories and 23 mentions for DexCom. DexCom's average media sentiment score of 1.65 beat Abbott Laboratories' score of 1.37 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 54 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 22 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor DXCM or AMN?

In the previous week, DexCom had 16 more articles in the media than AMN Healthcare Services. MarketBeat recorded 23 mentions for DexCom and 7 mentions for AMN Healthcare Services. DexCom's average media sentiment score of 1.65 beat AMN Healthcare Services' score of 0.72 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 22 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive AMN Healthcare Services 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ITGR or DXCM?

DexCom has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.84B 2.31 $102.81M $3.66 34.21 DexCom $4.66B 7.47 $836.30M $2.53 36.50

Is ITGR or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Integer's net margin of 6.97%. DexCom's return on equity of 35.94% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets Integer 6.97% 12.79% 6.48% DexCom 20.12% 35.94% 14.75%

Does the media prefer ITGR or DXCM?

In the previous week, DexCom had 16 more articles in the media than Integer. MarketBeat recorded 23 mentions for DexCom and 7 mentions for Integer. DexCom's average media sentiment score of 1.65 beat Integer's score of 1.42 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 22 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

DexCom (DXCM) Competitors

$92.34 +2.12 (+2.35%)

As of 08/21/2026 04:00 PM Eastern

Compare

DXCM vs. HQY, PODD, ABT, AMN, and ITGR

Should you buy DexCom stock or one of its competitors? DexCom's main competitors and comparable companies include HealthEquity (HQY), Insulet (PODD), Abbott Laboratories (ABT), AMN Healthcare Services (AMN), and Integer (ITGR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does DexCom compare to HealthEquity?

HealthEquity (NASDAQ:HQY) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

99.6% of HealthEquity shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.6% of HealthEquity shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthEquity	$1.31B	6.71	$215.20M	$2.67	39.48
DexCom	$4.66B	7.47	$836.30M	$2.53	36.50

DexCom has a net margin of 20.12% compared to HealthEquity's net margin of 17.25%. DexCom's return on equity of 35.94% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthEquity	17.25%	14.75%	9.22%
DexCom	20.12%	35.94%	14.75%

In the previous week, DexCom had 10 more articles in the media than HealthEquity. MarketBeat recorded 23 mentions for DexCom and 13 mentions for HealthEquity. DexCom's average media sentiment score of 1.65 beat HealthEquity's score of 1.40 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthEquity	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	22 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

HealthEquity currently has a consensus price target of $110.93, indicating a potential upside of 5.24%. DexCom has a consensus price target of $88.71, indicating a potential downside of 3.93%. Given HealthEquity's higher possible upside, equities research analysts plainly believe HealthEquity is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

HealthEquity has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, DexCom has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Summary

DexCom beats HealthEquity on 12 of the 17 factors compared between the two stocks.

How does DexCom compare to Insulet?

Insulet (NASDAQ:PODD) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, Insulet had 16 more articles in the media than DexCom. MarketBeat recorded 39 mentions for Insulet and 23 mentions for DexCom. DexCom's average media sentiment score of 1.65 beat Insulet's score of 0.42 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	11 Very Positive mention(s)	1 Positive mention(s)	27 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	22 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Insulet has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, DexCom has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Insulet currently has a consensus target price of $195.40, indicating a potential upside of 31.88%. DexCom has a consensus target price of $88.71, indicating a potential downside of 3.93%. Given Insulet's higher probable upside, analysts plainly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

97.8% of DexCom shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

DexCom has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.79	$247.10M	$5.35	27.69
DexCom	$4.66B	7.47	$836.30M	$2.53	36.50

DexCom has a net margin of 20.12% compared to Insulet's net margin of 12.29%. DexCom's return on equity of 35.94% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	12.29%	29.29%	13.31%
DexCom	20.12%	35.94%	14.75%

Summary

DexCom beats Insulet on 13 of the 17 factors compared between the two stocks.

How does DexCom compare to Abbott Laboratories?

Abbott Laboratories (NYSE:ABT) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Abbott Laboratories has higher revenue and earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	4.55	$6.52B	$3.09	37.74
DexCom	$4.66B	7.47	$836.30M	$2.53	36.50

DexCom has a net margin of 20.12% compared to Abbott Laboratories' net margin of 11.65%. DexCom's return on equity of 35.94% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	11.65%	17.69%	9.44%
DexCom	20.12%	35.94%	14.75%

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Abbott Laboratories has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, DexCom has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

In the previous week, Abbott Laboratories had 43 more articles in the media than DexCom. MarketBeat recorded 66 mentions for Abbott Laboratories and 23 mentions for DexCom. DexCom's average media sentiment score of 1.65 beat Abbott Laboratories' score of 1.37 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	54 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	22 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Abbott Laboratories presently has a consensus price target of $118.67, indicating a potential upside of 1.75%. DexCom has a consensus price target of $88.71, indicating a potential downside of 3.93%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, equities analysts plainly believe Abbott Laboratories is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	4 Hold rating(s)	20 Buy rating(s)	3 Strong Buy rating(s)	2.96
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Abbott Laboratories beats DexCom on 9 of the 17 factors compared between the two stocks.

How does DexCom compare to AMN Healthcare Services?

DexCom (NASDAQ:DXCM) and AMN Healthcare Services (NYSE:AMN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

DexCom has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

97.8% of DexCom shares are owned by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

DexCom has a net margin of 20.12% compared to AMN Healthcare Services' net margin of 3.06%. DexCom's return on equity of 35.94% beat AMN Healthcare Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	20.12%	35.94%	14.75%
AMN Healthcare Services	3.06%	19.92%	5.93%

DexCom currently has a consensus target price of $88.71, indicating a potential downside of 3.93%. AMN Healthcare Services has a consensus target price of $31.43, indicating a potential downside of 8.85%. Given DexCom's stronger consensus rating and higher possible upside, equities research analysts clearly believe DexCom is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

In the previous week, DexCom had 16 more articles in the media than AMN Healthcare Services. MarketBeat recorded 23 mentions for DexCom and 7 mentions for AMN Healthcare Services. DexCom's average media sentiment score of 1.65 beat AMN Healthcare Services' score of 0.72 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	22 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
AMN Healthcare Services	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	7.47	$836.30M	$2.53	36.50
AMN Healthcare Services	$2.73B	0.49	-$95.70M	$2.68	12.87

Summary

DexCom beats AMN Healthcare Services on 14 of the 17 factors compared between the two stocks.

How does DexCom compare to Integer?

Integer (NYSE:ITGR) and DexCom (NASDAQ:DXCM) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

DexCom has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.84B	2.31	$102.81M	$3.66	34.21
DexCom	$4.66B	7.47	$836.30M	$2.53	36.50

Integer currently has a consensus price target of $109.86, suggesting a potential downside of 12.27%. DexCom has a consensus price target of $88.71, suggesting a potential downside of 3.93%. Given DexCom's stronger consensus rating and higher possible upside, analysts clearly believe DexCom is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

Integer has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, DexCom has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

99.3% of Integer shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.1% of Integer shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

DexCom has a net margin of 20.12% compared to Integer's net margin of 6.97%. DexCom's return on equity of 35.94% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	6.97%	12.79%	6.48%
DexCom	20.12%	35.94%	14.75%

In the previous week, DexCom had 16 more articles in the media than Integer. MarketBeat recorded 23 mentions for DexCom and 7 mentions for Integer. DexCom's average media sentiment score of 1.65 beat Integer's score of 1.42 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	22 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

DexCom beats Integer on 14 of the 17 factors compared between the two stocks.

Get DexCom News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXCM vs. The Competition

Export

Metric	DexCom	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$34.85B	$6.02B	$7.37B	$12.85B
Dividend Yield	N/A	1.75%	2.53%	11.08%
P/E Ratio	36.50	26.67	272.60	24.24
Price / Sales	7.47	45.38	618.96	99.78
Price / Cash	33.35	33.24	78.62	53.99
Price / Book	13.29	6.23	13.05	6.20
Net Income	$836.30M	$150.07M	$3.47B	$348.59M
7 Day Performance	2.89%	0.69%	2.09%	0.08%
1 Month Performance	31.02%	8.91%	6.64%	3.88%
1 Year Performance	12.25%	8.07%	25.02%	16.98%

DexCom Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXCM DexCom	4.3199 of 5 stars	$92.34 +2.3%	$88.71 -3.9%	+12.3%	$34.85B	$4.66B	36.50	11,000	Positive News
HQY HealthEquity	4.0001 of 5 stars	$102.33 -2.3%	$110.93 +8.4%	+17.4%	$8.55B	$1.31B	38.33	2,814	News Coverage Positive News Upcoming Earnings Analyst Upgrade
PODD Insulet	4.8069 of 5 stars	$139.70 -2.5%	$195.40 +39.9%	-55.2%	$9.69B	$2.71B	26.11	5,400	Trending News
ABT Abbott Laboratories	4.5032 of 5 stars	$110.68 -0.5%	$118.67 +7.2%	-11.9%	$191.52B	$44.33B	35.82	115,000	Trending News
AMN AMN Healthcare Services	2.0824 of 5 stars	$34.46 -0.1%	$31.43 -8.8%	+66.7%	$1.33B	$2.73B	12.86	2,664

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXCM) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DexCom (DXCM) Competitors